1
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Viprey VF, Lastowska MA, Corrias MV,
Swerts K, Jackson MS and Burchill SA: Minimal disease monitoring by
QRT-PCR: guidelines for identification and systematic validation of
molecular markers prior to evaluation in prospective clinical
trials. J Pathol. 216:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kreissman SG, Seeger RC, Matthay KK,
London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL,
Diller L, et al: Purged versus non-purged peripheral blood
stem-cell transplantation for high-risk neuroblastoma (COG A3973):
a randomised phase 3 trial. Lancet Oncol. 14:999–1008. 2013.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Stutterheim J, Gerritsen A,
Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F,
Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: Detecting
minimal residual disease in neuroblastoma: the superiority of a
panel of real-time quantitative PCR markers. Clin Chem.
55:1316–1326. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Corrias MV, Haupt R, Carlini B, Cappelli
E, Giardino S, Tripodi G, Tonini GP, Garaventa A, Pistoia V and
Pistorio A: Multiple target molecular monitoring of bone marrow and
peripheral blood samples from patients with localized neuroblastoma
and healthy donors. Pediatr Blood Cancer. 58:43–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Cheung IY, Feng Y, Gerald W and Cheung NK:
Exploiting gene expression profiling to identify novel minimal
residual disease markers of neuroblastoma. Clin Cancer Res.
14:7020–7027. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hartomo TB, Kozaki A, Hasegawa D, Van
Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y,
Ohashi H, et al: Minimal residual disease monitoring in
neuroblastoma patients based on the expression of a set of
real-time RT-PCR markers in tumor-initiating cells. Oncol Rep.
29:1629–1636. 2013.PubMed/NCBI
|
10
|
Stutterheim J, Zappeij-Kannegieter L,
Versteeg R, Caron HN, van der Schoot CE and Tytgat GA: The
prognostic value of fast molecular response of marrow disease in
patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer.
47:1193–1202. 2011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Yáñez Y, Grau E, Oltra S, Cañete A,
Martínez F, Orellana C, Noguera R, Palanca S and Castel V: Minimal
disease detection in peripheral blood and bone marrow from patients
with non-metastatic neuroblastoma. J Cancer Res Clin Oncol.
137:1263–1272. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Castleberry RP, Pritchard J, Ambros P,
Berthold F, Brodeur GM, Castel V, Cohn SL, De Bernardi B,
Dicks-Mireaux C, Frappaz D, et al: The international neuroblastoma
risk groups (INRG): a preliminary report. Eur J Cancer.
33:2113–2116. 1997. View Article : Google Scholar : PubMed/NCBI
|
13
|
User Bulletin #2 ABI PRISM 7700 Sequence
Detection System. Applied Biosystem: Madrid (Spain). December 11,
(updated 10/2001). 1997.
|
14
|
Mordant P, Loriot Y, Lahon B, Castier Y,
Lesèche G, Soria JC, Massard C and Deutsch E: Minimal residual
disease in solid neoplasia: new frontier or red-herring? Cancer
Treat Rev. 38:101–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Vermeulen L, de Sousae Melo F, Richel DJ
and Medema JP: The developing cancer stem-cell model: clinical
challenges and opportunities. Lancet Oncol. 13:e83–e89. 2012.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Simon T, Hero B, Hunneman DH and Berthold
F: Tumour markers are poor predictors for relapse or progression in
neuroblastoma. Eur J Cancer. 39:1899–1903. 2003. View Article : Google Scholar : PubMed/NCBI
|